Videos

Chad A. Hamilton, MD, presents the case of a 49-year-old woman with BRCA wild-type ovarian cancer and offers his initial impressions.

Nathan Bahary, MD, PhD, discusses the ongoing challenge of chemotherapy drug shortages in the oncology field.

Everett E. Vokes, MD, discusses the clinical application of next-generation sequencing for head and neck cancers, including thyroid cancers.

Alicia K. Morgans, MD, MPH, discusses real-world evidence the shows patients with non-metastatic castration resistant prostate cancer on darolutamide have a longer time till discontinuation when compared with enzalutamide and apalutamide.

Raajit K. Rampal, MD, PhD, discusses the evolution of treatments for patients with myelofibrosis, and notes what he is excited to see more of in the future.

Nicholas J. Robert, MD, discusses a study of the social determinants of a patient’s health related to the use of genomic testing in women with breast cancer.

Catherine Lee reviews data on use of ibrutinib for steroid-refractory chronic graft versus host disease.

Experts in the treatment of graft versus host disease evaluate second-line agents for patients with steroid-refractory disease.

Important findings from the CARMEN-LC05 study evaluating tusa in combination with pembrolizumab and chemotherapy in NSCLC are discussed, highlighting their implications for clinical practice.

An overview of the CARMEN-LC03 and CARMEN-LC04 trials investigating tusa in different treatment settings for NSCLC and their impact on treatment approaches is provided.

Frederick Locke, MD, reviews the current landscape of approved CAR T-cell therapies for patients with large B-cell lymphoma and how off the shelf options like ALLO-501 and ALLO-501A can fill the gap for patients waiting for treatment.

Barbara Buttin, MD, provided insight on the phase 3 DUO-O trial and what it implies for the future of ovarian cancer treatment.

Funda Meric-Bernstam, MD, discusses the phase 2 DESTINY-PanTumor02 trial of fam-trastuzumab deruxtecan-nxki for the treatment of patients with HER2-expressing solid tumors.

Centering discussion on the first patient case, panelists reflect on the importance of ESR1 mutation in the setting of HR+/HER2- metastatic breast cancer.

Focused discussion on the evolving role of germline testing in HR+/HER2- metastatic breast cancer and how it may impact treatment pathways.

Joshua K. Sabari, MD, discusses LY3537982 for patients with KRAS G12C-mutant advanced solid tumors.

John Diaz, MD, discusses some known biomarkers in ovarian cancer and where he hopes to see more research in the future.

George Nahas, DO, discusses ongoing research that may shape the future treatment landscape of multiple myeloma.

Ben Derman, MD, discusses next steps for using minimal residual disease-guided discontinuation of maintenance therapy in patients with multiple myeloma.

Michael Wang, MD, discusses where future research efforts for pirtobrutinib will be focused for patients with relapsed/refractory mantle cell lymphoma.

Sagun Shrestha, MD, discusses new trials that are exploring anti PD-1 therapy in the first-line setting for patients with small cell lung cancer.

The categories of steroid refractory gvhd are discussed: intolerant, unresponsive, and dependent.

The group discusses treatment goals and patient education for chronic GVHD.

Amy Dezern, MD, MHS, closes her discussion by emphasizing the need for more treatments in MDS.

Following the 2023 ASCO Annual Meeting, Abdulraheem Yacoub, MD, reviews key data updates from the IMerge trial investigating imetelstat in patients with lower-risk MDS.

Matthew Powell, MD, discusses findings from the phase 3 RUBY/ENGOT-EN6/GOG3031/NSGO trial of dostarlimab in combination with chemotherapy for patients with mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer.

Daniel J. George, MD, offers closing thoughts and advice to community oncologists who treat patients with prostate cancer.

Clinical insights on managing adverse events associated with PARP inhibitor therapy in patients with prostate cancer.

Daniel J. George, MD, provides insights on how to treat patients with prostate cancer who have pathogenic non-BRCA HRD mutations, and his approach when patients progress on a PARP inhibitor.

A medical oncologist discusses situations in which he might recommend abiraterone alongside a PARP inhibitor as first-line treatment for patients with mCRPC.